An RNA biotech draws the blueprint for a late-stage Dravet syndrome trial and beyond

The 2020s are shaping up to be a golden age for RNA. From COVID-19 vaccines to rare disease treatments, RNA has become key to tackling many of biotech’s tough obstacles.

Stoke Therapeutics is bringing that RNA revolution to difficult neurological diseases that primarily affect children, including the severe form of epilepsy called Dravet syndrome, the genetic cause of which has only recently been understood, said Stoke CEO Dr. Ed Kaye.